Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch
  

Intermune Inc patents

Recent patent applications related to Intermune Inc. Intermune Inc is listed as an Agent/Assignee. Note: Intermune Inc may have other listings under different names/spellings. We're not affiliated with Intermune Inc, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Intermune Inc-related inventors




Date Intermune Inc patents (updated weekly) - BOOKMARK this page
11/02/17Lpa-associated protein and rna expression
05/11/17Methods of administering pirfenidone therapy
05/04/17Anti-fibrotic pyridinones
04/13/17Pirfenidone treatment for patients with atypical liver function
04/06/17Method of modulating stress-activated protein kinase system
03/23/17Methods of administering pirfenidone therapy
11/10/16Method of providing pirfenidone therapy to a patient
10/20/16Methods of administering pirfenidone therapy
09/15/16Anti-fibrotic pyridinones
09/01/16Pirfenidone treatment for patients with atypical liver function
08/11/16Methods of administering pirfenidone therapy
03/17/16Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone
01/28/16Methods of improving microvascular integrity
12/24/15Method for synthesizing pirfenidone
12/03/15Pirfenidone therapy and inducers of cytochrome p450
09/24/15Anti-fibrotic pyridinones
07/30/15Pharmaceutical composition containing as an active ingredient 5-methyl -1-phenyl-2-(1h)-pyridone
06/18/15Pirfenidone and anti-fibrotic therapy in selected patients
04/23/15Pirfenidone therapy and inducers of cytochrome p450
03/05/15Method for synthesizing pirfenidone
09/25/14Proteomic ipf markers
08/28/14Method for preparing a granulate formulation of pirfenidone and pharmaceutically acceptable excipients
08/21/14Compounds and methods for treating inflammatory and fibrotic disorders
08/14/14Method of modulating stress-activated protein kinase system
08/07/14Altering pharmacokinetics of pirfenidone therapy
08/07/14Method for synthesizing pirfenidone
03/13/14Pirfenidone treatment for patients with atypical liver function
03/06/14Methods of administering pirfenidone therapy
12/26/13Method for synthesizing pirfenidone
08/29/13Method of providing pirfenidone therapy to a patient
08/29/13Altering pharmacokinetics of pirfenidone therapy
06/27/13Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
06/13/13Methods of diagnosing and treating idiopathic pulmonary fibrosis
04/25/13Compounds and methods for treating inflammatory and fibrotic disorders
03/21/13Lysophosphatidic acid receptor antagonists
02/21/13Pirfenidone therapy and inducers of of cytochrome p450
10/11/12Method of modulating stress-activated protein kinase system
08/16/12Novel macrocyclic inhibitors of hepatitis c virus replication
04/26/12Novel macrocyclic inhibitors of hepatitis c virus replication
04/19/12Novel inhibitors of hepatitis c virus replication
04/19/12Substituted proline inhibitors of hepatitis c virus replication
04/12/12Pirfenidone therapy and inducers of cytochrome p450
03/29/12Pirfenidone treatment for patients with atypical liver function
02/23/12Methods of treating atrial fibrillation with p38 inhibitor compounds
01/19/12Methods of treating hiv patients with anti-fibrotics
01/19/12Granulate formulation of pirfenidone and pharmaceutically acceptable excipients
01/19/12Methods of administering pirfenidone therapy
01/19/12Method for synthesizing pirfenidone
12/29/11Methods of administering pirfenidone therapy
12/22/11Novel inhibitors of hepatitis c virus replication
10/27/11Pirfenidone treatment for patients with atypical liver function
09/08/11Pirfenidone/toll-like receptor (tlr) agonist compounds and methods of treating neutropenia
07/21/11Use of alpha-glucosidase inhibitors to treat alphavirus infections
07/14/11Pirfenidone therapy and inducers of cytochrome p450
07/07/11Methods of administering pirfenidone therapy
06/23/11Novel inhibitors of hepatitis c virus replication
06/09/11Altering pharmacokinetics of pirfenidone therapy
06/02/11Novel macrocyclic inhibitors of hepatitis c virus replication
05/12/11Novel inhibitors of hepatitis c virus replication
04/07/11Novel macrocyclic inhibitors of hepatitis c virus replication
04/07/11Therapeutic antiviral peptides
03/10/11Novel macrocyclic inhibitors of hepatitis c virus replication
02/10/11Method of modulating stress-activated protein kinase system
01/06/11Method for synthesizing pirfenidone
12/23/10Method of providing pirfenidone therapy to a patient
Patent Packs
08/19/10Novel inhibitors of hepatitis c virus replication
06/17/10Use of alpha-glucosidase inhibitors to treat alphavirus infections
06/17/10Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
05/13/10Therapeutic antiviral peptides
12/24/09Compounds and methods for treating inflammatory and fibrotic disorders
10/29/09Novel macrocyclic inhibitors of hepatitis c virus replication
10/15/09Novel inhibitors of hepatitis c virus replication
09/03/09Hcv genotyping and phenotyping
02/19/09Novel inhibitors of hepatitis c virus replication







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Intermune Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Intermune Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';